10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $113.6 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 5.28% year-over-year to $113.6 million; the TTM figure through Mar 2026 stood at $113.6 million (up 5.28% YoY), while the FY2025 annual figure was $153.5 million, up 30.45% from the prior year.
• Total Current Liabilities came in at $113.6 million for Q1 2026 at 10x Genomics, down from $153.5 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $153.5 million in Q4 2025 to a low of $94.4 million in Q1 2022.
• A 5-year average of $118.0 million and a median of $113.6 million in 2026 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities decreased 21.65% in 2022 and soared 30.45% in 2025, its largest moves.
• 10x Genomics' Total Current Liabilities stood at $131.0 million in 2022, then declined by 2.9% to $127.2 million in 2023, then slipped by 7.49% to $117.6 million in 2024, then surged by 30.45% to $153.5 million in 2025, then fell by 25.97% to $113.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $113.6 million, $153.5 million, and $147.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison